<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595617</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/41</org_study_id>
    <nct_id>NCT04595617</nct_id>
  </id_info>
  <brief_title>Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)</brief_title>
  <acronym>TAAS</acronym>
  <official_title>Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aim to correlate risk factors (genetic, therapeutic and socio-demographic&#xD;
      factors) to anti-αIIbβ3 antibodies formation following blood products transfusion (platelets&#xD;
      or packed red cells) or pregnancy in a national cohort of GT patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glanzmann thrombasthenia (GT) is a rare autosomal recessive disorder caused by the absence or&#xD;
      the dysfunction of the αIIbβ3 integrin, the most abundant receptor on platelets that mediates&#xD;
      platelet aggregation through its binding of adhesive proteins. GT is readily identifiable by&#xD;
      platelet function testing, and a lack of platelet aggregation in response to all&#xD;
      physiological agonists is unique for this disease. The ITGA2B gene encodes for the αIIb&#xD;
      subunit, whereas the ITGB3 gene encodes for β3. Mutations causing GT can affect either ITGA2B&#xD;
      or ITGB3. The disease is characterized by spontaneous and trauma-related mucocutaneous&#xD;
      bleeding, with variable expression ranging from easy bruising to fatal hemorrhages. Platelet&#xD;
      transfusions are used to control or prevent life-threatening blood loss, but can become&#xD;
      ineffective due to naturally occurring antibodies directed against αIIbβ3. Such antibodies&#xD;
      are produced when patient's immune system comes into contact with normal αIIbβ3 expressing&#xD;
      platelets.&#xD;
&#xD;
      There is no currently consensus concerning the frequency, the long-term evolution, or the&#xD;
      formation of characteristics of antibodies from GT patients in relation to the nature of the&#xD;
      defective gene (ITGA2B or ITGB3), gene variations or other factors. Research are needed to&#xD;
      confirm that nature of the gene defect may have a causative role in antibody development.&#xD;
      Moreover, strength and persistence of antibodies may vary among patients with the same&#xD;
      mutation, suggesting that other factors, such as immune modifiers genes, play a role in&#xD;
      shaping antibody repertoire.&#xD;
&#xD;
      Monoclonal antibody-specific immobilization of platelet antigens (MAIPA) is still considered&#xD;
      as the reference method for evaluating the presence of anti-αIIbβ3 antibodies in GT patients.&#xD;
      All the tests will be performed by the principal investigator site (Bordeaux).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of change of an anti-αIIbβ3 immunization</measure>
    <time_frame>From inclusion to 18 months visit</time_frame>
    <description>Characterization of change of an anti-αIIbβ3 immunization will be assessed with Indirect MoAb-specific immobilization of platelet antigens (MAIPA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with positive anti-αIIbβ3 antibodies in relation to risk factors</measure>
    <time_frame>From inclusion to 18 months visit</time_frame>
    <description>Risk factors could be subtype of GT, year of birth, ITGA2B or ITGB3 gene mutation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the prevalence of anti-αIIbβ3 antibodies in a regional cohort of GT patients</measure>
    <time_frame>From inclusion to 18 months visit</time_frame>
    <description>Presence of anti-αIIbβ3 antibodies will be assessed with Indirect MoAb-specific immobilization of platelet antigens (MAIPA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the kinetic of an anti-αIIbβ3 immunization following blood transfusion</measure>
    <time_frame>At 7-10 days and 1 month (+/-2 weeks) after each blood transfusion</time_frame>
    <description>Repetition of the antibodies measurements with Indirect MoAb-specific immobilization of platelet antigens (MAIPA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the mechanism of anti-αIIbβ3 antibodies blocking integrin function by determining the capacity of anti-αIIbβ3 antibodies to impair fibrinogen binding</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>In vitro studies will be performed by mixing serum of patients with washed donors' platelets and inhibition of the integrin will be studied by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glanzmann Thrombasthenia</condition>
  <arm_group>
    <arm_group_label>Patients with diagnosis of Glanzmann Thrombastenia (GT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antibodies screening</intervention_name>
    <description>All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.</description>
    <arm_group_label>Patients with diagnosis of Glanzmann Thrombastenia (GT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with a clear diagnosis of Glanzmann Thrombastenia (GT), whatever the&#xD;
             subtype of disease.&#xD;
&#xD;
          -  Affiliated person or beneficiary of a social security scheme.&#xD;
&#xD;
          -  Free, informed and written consent signed by the participant, or parents or legal&#xD;
             representant for the child population, and the investigator (at the latest on the day&#xD;
             of inclusion and before any examination required by the research).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current treatment that may interfere with anti-αIIbβ3 antibodies detection, such as&#xD;
             intravenous immunoglobulins within the previous month.&#xD;
&#xD;
          -  Psychiatric, social or behavioral condition judged to be non-compatible with the&#xD;
             respect of the protocol, including good observance of treatment and compliance to&#xD;
             follow-up.&#xD;
&#xD;
          -  Adult protected by the law.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu FIORE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu FIORE</last_name>
    <phone>+33 (0)5 57 65 64 78</phone>
    <email>mathieu.fiore@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathieu FIORE</last_name>
    <email>mathieu.fiore@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu FIORE</last_name>
      <email>mathieu.fiore@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoan HUGUENIN</last_name>
      <email>yoann.huguenin@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre, APHP</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roseline D'OIRON</last_name>
      <email>roseline.doiron@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline OUDOT</last_name>
      <email>caroline.oudot@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital la Timone, APHM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine ALESSI</last_name>
      <email>marie-christine.alessi@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Géraldine LAVIGNE</last_name>
      <email>geraldine.lavigne@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu PUYADE</last_name>
      <email>mathieu.puyade@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique DESPREZ</last_name>
      <email>dominique.desprez@chu-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie VOISIN</last_name>
      <email>voisin.s@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glanzmann thrombasthenia</keyword>
  <keyword>anti-GPIIb-IIIa immunization</keyword>
  <keyword>MAIPA</keyword>
  <keyword>Platelet transfusions</keyword>
  <keyword>Recombinant activated factor VII</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombasthenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

